Copyright ©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Infect Dis. Nov 25, 2015; 5(4): 59-66
Published online Nov 25, 2015. doi: 10.5495/wjcid.v5.i4.59
New biomarkers for clinical management of hepatitis C virus infected patients
Alessandra Biasiolo, Andrea Martini, Patrizia Pontisso
Alessandra Biasiolo, Andrea Martini, Patrizia Pontisso, Department of Medicine, University of Padua, 35128 Padua, Italy
Author contributions: Biasiolo A designed the study, acquired data and drafted the article; Martini A acquired data and reviewed the manuscript; Pontisso P conceived the study and made the final critical revision of the manuscript; all authors had seen and approved the final version of the manuscript.
Supported by University of Padua (found 2011 - prot. No. STPD11RYPT_003).
Conflict-of-interest statement: All the authors declare no conflicting interests.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Patrizia Pontisso, Professor, Department of Medicine, University of Padua, Via Giustiniani, 2, 35128 Padua, Italy. patrizia@unipd.it
Telephone: +39-49-8217872 Fax: +39-49-8754179
Received: July 11, 2015
Peer-review started: July 15, 2015
First decision: August 25, 2015
Revised: August 28, 2015
Accepted: October 16, 2015
Article in press: October 19, 2015
Published online: November 25, 2015
Core Tip

Core tip: Hepatitis C virus (HCV) infection is a major cause of cirrhosis and hepatocellular carcinoma (HCC), leading to liver failure and/or liver transplantation. The current knowledge on the new promising biomarkers, able to predict the progression of HCV-related liver disease and HCC, has been the focus of this editorial.